Results 71 to 80 of about 2,929 (206)

Fourteen-Day Vonoprazan-Based Bismuth Quadruple Therapy for H. pylori Eradication in an Area With High Clarithromycin and Levofloxacin Resistance: A Prospective Randomized Study (Vq-HP Trial) [PDF]

Potassium-competitive acid blockers (P-CABs) provide potent acid inhibition, yet studies on P-CAB-based quadruple therapy for H. pylori eradication are limited.
Bongkotvirawan, Phubordee, Eiamsitrakoon, Thanee, Gamnarai, Pornpen, Pawa, Kammal Kumar, Ratana-Amornpin, Sarita, Siramolpiwat, Sith, Tungtrongchitr, Nuttapat, Vilaichone, Ratha-Korn, Wongcha-Um, Arti, Yamaoka, Yoshio   +9 more
core   +2 more sources

Evaluation of Delayed Bleeding Prevention and Sustained Closure Using the Reopenable Clip‐Over‐the‐Line Method for Gastric Endoscopic Submucosal Dissection

DEN Open, Volume 6, Issue 1, April 2026.
ROLM achieves complete closure of post‐ESD mucosal defects and is associated with no delayed bleeding in high‐risk patients. Complete closure is confirmed in 100% of lesions on postoperative day 1, and clip retention at 2 months remains high, suggesting the potential for durable performance of ROLM.
Gen Kitahara, Takuya Wada, Kenta Murotani, Kusutaro Doi, Toshiki Horii, Tomohiro Betto, Akinori Watanabe, Kenji Ishido, Hisatomo Ikehara, Chika Kusano   +9 more
wiley   +1 more source

Evolving therapeutics in acid-related disorders of the gut: is vonoprazan the drug of the next decade [PDF]

Vonoprazan a competitive potassium acid blocker (P-CAB) has been gaining traction compared to the use of traditional PPIs for the treatment of GERD and other acid-related disorders.
Bharadwaj , Sanket, Bhowmik, Subham, Panchal, Ishita, Panchal, Viraj, Roy, Mehak, Shah, Abhi, Shah, Vedant   +6 more
core   +2 more sources

The Impact of Vonoprazan on Tacrolimus Blood Levels in Transplant Recipients: A Systematic Review and Meta-Analysis [PDF]

Background: Tacrolimus is essential for immunosuppression in transplant recipients but presents risks of toxicity and rejection due to its narrow therapeutic window.
Baddoura, Walid, Elgendy, Mohamed S., Elsawy, Omar K., Elshewikh, Mohamed A., Ezz, Mohamed R., Hussein, Abdallah, Rajab, Islam, Tempera, Patrick, Wagdy, Mohamed   +8 more
core   +2 more sources

Tegoprazan in Gastroesophageal Reflux Disease and Related Acid‐Mediated Conditions: A Systematic Review and Meta‐Analysis

JGH Open, Volume 10, Issue 4, April 2026.
ABSTRACT Gastroesophageal reflux disease (GERD) is a chronic relapsing disorder often inadequately controlled with proton pump inhibitors (PPIs), particularly in patients with nocturnal acid breakthrough (NAB) or non‐erosive reflux disease (NERD). Tegoprazan, a potassium‐competitive acid blocker (PCAB), offers rapid, potent, and CYP2C19‐independent ...
Sanjay Bandyopadhyay, Mahesh Goenka, Debapratim Routh, G. N. Ramesh, Parimal Lawate   +4 more
wiley   +1 more source

Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial

Chinese Medical Journal
. Background:. Erosive esophagitis (EE) is a gastroesophageal reflux disease characterized by mucosal breaks in the esophagus. Proton pump inhibitors are widely used as maintenance therapy for EE, but many patients still relapse.
Yinglian Xiao, Jiaming Qian, Shutian Zhang, Ning Dai, Hoon Jai Chun, Chengtang Chiu, Chui Fung Chong, Nobuo Funao, Yuuichi Sakurai, Jessica D. Eisner, Li Xie, Minhu Chen, Xiangxiang Pan, Peifang Wei   +13 more
doaj   +1 more source

Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms

Trials, 2023
Background Vonoprazan results in more potent acid suppression for gastroesophageal reflux disease (GERD) than proton pump inhibitors. It has only been approved for treating erosive esophagitis in China, but 30–40% of GERD patients cannot achieve the goal
Dongke Wang, Dan Zhou, Xinghuang Liu, Zhiyue Xu, Tao Bai, Xiaohua Hou   +5 more
doaj   +1 more source

Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Tyrosine kinase inhibitors (TKIs) are essential in treating chronic myeloid leukaemia (CML) and other malignancies. Their absorption, however, is highly pH‐dependent, making them susceptible to interactions with acid‐suppressing agents such as proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs) and antacids ...
Marek Lapka, Anna Khryakova, Anastasiia Nazmutdinova, Chrysostomos Charalambous, Jan Bosak, Jiri Sliva   +5 more
wiley   +1 more source

Biodegradable Adhesive Systems for Bio‐Integrated Applications

Advanced Science, Volume 13, Issue 15, 13 March 2026.
Biodegradable adhesives provide temporary yet reliable adhesion while degrading into safe, non‐toxic by‐products under physiological or environmental conditions. This review summarizes recent developments in physical and chemical adhesion mechanisms—including hydrogen bonding, catechol chemistry, amine‐carboxyl coupling, and emerging diazirine and urea
Won Bae Han, Sungkeun Han, Prashant Shivaji Shewale, Hyewon Cho, Li‐Hyun Kim, Venkata Ramesh Naganaboina, Suk‐Won Hwang   +6 more
wiley   +1 more source

Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy for Helicobacter pylori eradication in a high-resistance, multi-ethnic region: a multicenter study in Guizhou, China

Frontiers in Medicine
IntroductionWhile vonoprazan-amoxicillin dual therapy has achieved > 90% eradication rates for Helicobacter pylori (H. pylori) in clinical trials, its effectiveness in “real-world” regions with high primary antibiotic resistance and ethnic diversity ...
Yurong Huang, Yurong Huang, Juan Zheng, Zhengyi Yang, Daili Li, Hua Wu, Wenzhong Chen, Wenjuan Wang, Min Gan, Changmei Shi, Dongmei Xie, Canyu Zhan, Gengqing Song, Jie Yang   +13 more
doaj   +1 more source